Ankylosing Spondylitis and the Gut Microbiome: Clinical Links

Ankylosing spondylitis (AS) is a chronic inflammatory autoimmune disease that primarily affects the spine and sacroiliac joints, leading to pain, stiffness, and progressive fusion of the vertebrae. It belongs to a group of disorders known as axial spondyloarthritis (axSpA). Although the exact cause of AS remains unclear, growing research has identified a significant relationship between the gut microbiome, intestinal inflammation, and immune system dysregulation. This gut-joint connection has become one of the most promising areas of investigation in understanding disease progression and developing future management approaches.

Approximately 90–95% of patients with ankylosing spondylitis carry the HLA-B27 gene, but genetic susceptibility alone is insufficient to cause disease. Many people who possess HLA-B27 never develop AS, suggesting that environmental factors, including alterations in the gut microbiome, are important triggers.

Studies have shown that up to 60% of patients with ankylosing spondylitis have microscopic intestinal inflammation, even when they have no digestive symptoms. Furthermore, around 5–10% of individuals with AS eventually develop inflammatory bowel diseases (IBD) such as Crohn's disease or ulcerative colitis. This overlap strongly supports a shared inflammatory pathway involving the gut.

The healthy gut microbiome consists of trillions of bacteria that help regulate digestion, nutrient absorption, and immune function. In AS, researchers have consistently identified gut dysbiosis, an imbalance in these microbial communities. Reduced levels of beneficial bacteria such as Faecalibacterium prausnitzii and increased numbers of potentially pro-inflammatory organisms have been reported. These microbial alterations may impair the integrity of the intestinal lining, producing what is commonly known as a "leaky gut."

When the intestinal barrier becomes more permeable, bacterial fragments such as lipopolysaccharides (LPS) and other microbial products can enter the bloodstream. These substances activate immune cells, stimulating the release of inflammatory cytokines including tumour necrosis factor-alpha (TNF-α), interleukin-17 (IL-17), and interleukin-23 (IL-23). These cytokines play central roles in the inflammation characteristic of ankylosing spondylitis, driving pain, stiffness, bone erosion, and abnormal new bone formation.

The IL-23/IL-17 immune pathway represents one of the potent mechanistic links between gut inflammation and spinal disease. Immune cells within the intestinal lining can become activated by microbial imbalance and subsequently migrate to the joints and entheses (where tendons and ligaments attach to bone), perpetuating chronic inflammation. This understanding has led directly to the development of modern biologic therapies targeting IL-17 and TNF-α, both of which have significantly improved outcomes for many patients.

Short-chain fatty acids (SCFAs), particularly butyrate, are beneficial compounds produced by healthy gut bacteria during the fermentation of dietary fibre. Butyrate supports the intestinal barrier and promotes regulatory immune cells that suppress excessive inflammation. Reduced production of SCFAs has been observed in several autoimmune diseases, including AS, potentially contributing to immune dysfunction.

Lifestyle factors that influence the microbiome may therefore play a supportive role alongside conventional management approaches. Diets rich in fibre, fruits, vegetables, legumes, and fermented foods encourage beneficial bacterial growth and SCFA production. Regular exercise, adequate sleep, stress management, and avoiding smoking may also positively influence both the microbiome and systemic inflammation. While probiotics have shown some promise in experimental studies, current clinical evidence is insufficient to recommend them as a standalone management approaches for ankylosing spondylitis.

In conclusion, accumulating evidence demonstrates that ankylosing spondylitis is not solely a disease of the spine but also involves complex interactions between the gut microbiome, intestinal barrier, genetics, and immune system. Gut dysbiosis appears to contribute to chronic inflammation through increased intestinal permeability and activation of inflammatory immune pathways. Although biologic medications remain the cornerstone of management approaches, improving gut health through nutrition and lifestyle may provide valuable complementary support. As research continues, therapies aimed at restoring a healthy microbiome may become an important component of personalised management approaches strategies for ankylosing spondylitis.

Get In Touch

https://maxilinreview.com/fingersjones